Energex proposes HemoModulation therapy for treatment of H1N1 swine flu
8 May 2009
Energex Systems Inc. has announced that it has notified the FDA of its interest in applying for an Emergency Use Approval that would permit the company to offer its HemoModulation therapy for the treatment of influenza type A(H1N1), otherwise known as swine flu.
HemoModulation therapy was shown to inactivate the virus in mice. This same therapy has been under review by the FDA and is in human clinical trials for Hepatitis C and HIV.
HemoModulation therapy is a process using precise amounts of UVC energy on a small sample of the patient's blood to inactivate the particular strain of virus that the patient is infected with, and returning the blood to the body. The hypothesis is that UV inactivated virus will serve as an autologous vaccine and boost the immune system of the patient against their particular strain of virus.
The process takes approximately 30 minutes and can be administered in an office, lab or any other healthcare facility.
In animal studies, says Thomas Petrie, the company’s Director of Research & Development, the therapy produced discernable and substantial improvement in both clinical disease and pulmonary function in mice infected with the H1N1 virus.
Minimal clinical illness was observed up to 9 days post infection for those animals that were treated. In contrast, the SHAM-treated animals developed severe illness by day 6 that did not significantly resolve through the 13-day course of the study.
As measured by pulmonary lung function testing, infected animals that were treated with HemoModulation therapy exhibited a significantly greater ability to breathe relative to their sham-treated counterparts and pathological examination of lungs clearly indicated that treatment significantly inhibited virus induced inflammation resulting in airways that were for the most part, clear of inflammatory cells and cellular debris.
In contrast, the lungs of the sham-treated animals had airways that were filled with inflammatory cells and blood, and exhibited substantial destruction of cells lining the airways.
Bookmark this page